ASP Isotopes (NASDAQ:ASPI) Stock Price Down 8.9% – Should You Sell?

Shares of ASP Isotopes Inc. (NASDAQ:ASPI) traded down 8.9% during mid-day trading on Tuesday . The company traded as low as $5.53 and last traded at $5.6090. 1,701,517 shares changed hands during trading, a decline of 61% from the average session volume of 4,385,148 shares. The stock had previously closed at $6.16.

Analyst Ratings Changes

ASPI has been the subject of several research analyst reports. Loop Capital set a $15.00 price objective on shares of ASP Isotopes in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Tuesday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Monday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Stock Performance

The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The company has a market cap of $656.17 million, a price-to-earnings ratio of -4.55 and a beta of 3.28. The stock has a 50-day moving average price of $9.33 and a 200 day moving average price of $8.81.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $2.25 million. As a group, analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $8.39, for a total value of $680,236.03. Following the sale, the chief executive officer directly owned 8,084,191 shares in the company, valued at $67,826,362.49. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Gorley sold 64,000 shares of the firm’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $9.75, for a total value of $624,000.00. Following the completion of the transaction, the director owned 81,360 shares of the company’s stock, valued at $793,260. The trade was a 44.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 473,699 shares of company stock valued at $4,225,902 over the last ninety days. Insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On ASP Isotopes

Several large investors have recently made changes to their positions in the stock. Penn Capital Management Company LLC increased its holdings in ASP Isotopes by 983.0% during the third quarter. Penn Capital Management Company LLC now owns 202,144 shares of the company’s stock worth $1,945,000 after buying an additional 183,479 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of ASP Isotopes by 331.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 12,622 shares of the company’s stock valued at $121,000 after purchasing an additional 9,695 shares during the period. Advisory Services Network LLC lifted its stake in ASP Isotopes by 125.8% in the 3rd quarter. Advisory Services Network LLC now owns 31,238 shares of the company’s stock valued at $301,000 after purchasing an additional 17,403 shares during the last quarter. NewEdge Advisors LLC bought a new position in ASP Isotopes during the third quarter worth about $211,000. Finally, XTX Topco Ltd grew its holdings in ASP Isotopes by 478.7% during the third quarter. XTX Topco Ltd now owns 139,782 shares of the company’s stock worth $1,345,000 after purchasing an additional 115,627 shares during the period. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.